{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Appendicitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Atelectasis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bronchial obstruction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bronchopulmonary hemorrhage"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cataract"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Headache"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypophosphatemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypoxia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lung infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphocyte count increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Menorrhagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Mucositis oral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non cardiac chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Oral pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"PNEUMONIA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Thromboembolic event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Wound complication"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Toxicity will be tabulated via frequency distributions, and also dichotomized to report the proportion (and percentage) of patients experiencing a specified level (e.g., grade 3-4) of toxicity.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}